Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction

Experimental Neurology

Volumn 219, Issue 2, 2009, Pages 533-542

  Stockwell, K A ^a   Scheller, D ^c   Rose, S ^a   Jackson, M J ^a   Tayarani Binazir, K ^a   Iravani, M M ^a   Smith, L A ^a   Olanow, C W ^b   Jenner, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Pharmacology/Toxicology   (Germany)

Author keywords

Continuous delivery; Dyskinesia; l DOPA; MPTP; Parkinson's disease; Primates; Rotigotine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; LEVODOPA; ROTIGOTINE; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSKINESIA; FEMALE; MALE; MARMOSET; MONOTHERAPY; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; TREATMENT DURATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MALE; MOTOR ACTIVITY; MOTOR SKILLS; MPTP POISONING; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 69949101386     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.07.011     Document Type: Article

References (44)

1. Bartoszyk G.D., Van A.C., Greiner H.E., Rautenberg W., Russ H., and Seyfried C.A. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J. Neural Transm. 111 (2004) 113-126
2. Belluzzi J.D., Domino E.F., May J.M., Bankiewicz K.S., and McAfee D.A. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov. Disord. 9 (1994) 147-154
3. Bibbiani F., Costantini L.C., Patel R., and Chase T.N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol. 192 (2005) 73-78
4. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., Di P.T., Walters R.R., and Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272 (1995) 854-859
5. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 20 (2005) 919-931
6. de la Fuente-Fernandez R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., Lee C.S., Ruth T.J., Calne D.B., and Stoessl A.J. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann. Neurol. 49 (2001) 298-303
7. Domino E.F., and Sheng J. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 265 (1993) 1387-1391
8. Elshoff J.P., Cawello W., Braun M., and Horstmann R. Stable rotigotine plasma concentrations over 24 hours in patients with early-stage Parkinson's disease after once-daily transdermal administration of rotigotine (Neupro). Neurology 66 (2006) A293
9. Fox S.H., Lang A.E., and Brotchie J.M. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov. Disord. 21 (2006) 1578-1594
10. Gancher S.T., Nutt J.G., and Woodward W.R. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov. Disord. 10 (1995) 37-43
11. Grace A.A. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend. 37 (1995) 111-129
12. Gregoire L., Samadi P., Graham J., Bedard P.J., Bartoszyk G.D., and Di P.T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys. Parkinsonism Relat. Disord. 15 (2009) 445-452
13. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., and Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J. Pharmacol. Exp. Ther. 319 (2006) 1225-1234
14. Jackson M.J., Smith L.A., Al-Barghouthy G., Rose S., and Jenner P. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp. Neurol. 204 (2007) 162-170
15. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. 47 (2000) S90-S99
16. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev., Neurosci. 9 (2008) 665-677
17. Kehr J., Hu X.J., Goiny M., and Scheller D.K. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J. Neural Transm. 114 (2007) 1027-1031
18. Larramendy C., Taravini I.R., Saborido M.D., Ferrario J.E., Murer M.G., and Gershanik O.S. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behav. Brain Res. 194 (2008) 44-51
19. Linazasoro G., Van B.N., Ugedo L., and Ruiz Ortega J.A. Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?. J. Neural Transm. 115 (2008) 431-441
20. Löschmann P.A., Chong P.N., Nomoto M., Tepper P.G., Horn A.S., Jenner P., and Marsden C.D. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. Eur. J. Pharmacol. 166 (1989) 373-380
21. Miller D.W., and Abercrombie E.D. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J. Neurochem. 72 (1999) 1516-1522
22. Morgan J.C., and Sethi K.D. Rotigotine for the treatment of Parkinson's disease. Expert Rev. Neurotherapeutics 6 (2006) 1275-1282
23. Nyholm D., Lewander T., Johansson A., LeWitt P.A., Lundqvist C., and Aquilonius S.M. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin. Neuropharmacol. 31 (2008) 63-73
24. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (2000) S2-S7
25. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F., and Russ H. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27 (2004) 58-62
26. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study. Parkinson Study Group. Clin. Neuropharmacol. 23 (2000) 34-44
27. Rascol O., Arnulf I., Peyro-Saint P.H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Bejjani B., Fabre N., Montastruc J.L., and Agid Y. Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16 (2001) 708-713
28. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., and Abdalla M. Development of dyskinesias in a 5-year trial of ropinirole and l-dopa. Mov. Disord. 21 (2006) 1844-1850
29. Rose S., Scheller D.K., Breidenbach A., Smith L., Jackson M., Stockwell K., and Jenner P. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav. Pharmacol. 18 (2007) 155-160
30. Savola J.M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S.G., Fox S.H., Crossman A.R., and Brotchie J.M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 18 (2003) 872-883
31. Scheller D., Durmuller N., Moser P., and Porsolt R.D. Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with the sleep-wake cycle in the rat. Eur. J. Pharmacol. 584 (2008) 111-117
32. Scheller D., Ullmer C., Berkels R., Gwarek M., and Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn-Schmiedebergs Arch. Pharmacol 379 (2008) 73-86
33. Schmidt W.J., Lebsanft H., Heindl M., Gerlach M., Gruenblatt E., Riederer P., Mayerhofer A., and Scheller D.K. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J. Neural Transm. 115 (2008) 1385-1392
34. Smith L., De Salvia M., Jenner P., and Marsden C.D. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov. Disord. 11 (1996) 125-135
35. Smith L.A., Jackson M.J., Hansard M.J., Maratos E., and Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov. Disord. 18 (2003) 487-495
36. Smith L.A., Jackson M.J., Johnston L., Kuoppamaki M., Rose S., Al-Barghouthy G., Del Signore S., and Jenner P. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin. Neuropharmacol. 29 (2006) 112-125
37. Stocchi F., Ruggieri S., Vacca L., and Olanow C.W. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125 (2002) 2058-2066
38. Stocchi F., Vacca L., Ruggieri S., and Olanow C.W. Intermittent vs. continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol. 62 (2005) 905-910
39. Stockwell K.A., Virley D.J., Perren M., Iravani M.M., Jackson M.J., Rose S., and Jenner P. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp. Neurol. 211 (2008) 172-179
40. Swart P.J., and de Zeeuw R.A. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 47 (1992) 613-615
41. Vaamonde J., Luquin M.R., and Obeso J.A. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 114 Pt 1B (1991) 601-617
42. Van der Weide J., De Vries J.B., Tepper P.G., Krause D.N., Dubocovich M.L., and Horn A.S. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models. Eur. J. Pharmacol. 147 (1988) 249-258
43. Walters D.R., McConnell W.R., and Cefali E.A. Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. J. Pharm. Sci. 83 (1994) 758-760
44. Zareba G. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. Drugs Today (Barc.) 42 (2006) 21-28